As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects?

As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects?

As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology Chairman of the Department of Cardiology Heartcenter of the University Medical Center Nijmegen, The Netherlands